Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595

NCT05522387 is registered in ClinicalTrials.gov with Inmune Bio, Inc. as lead sponsor.

NCT NCT05522387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05522387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595
Lead sponsor
Inmune Bio, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
February 21, 2023
Completion date
July 5, 2024
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, brain diseases, central nervous system diseases, dementia, mental disorders, nervous system diseases, neurocognitive disorders, neurodegenerative diseases, tauopathies